Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants.

RPEP-163632026Wang, Min; Yang, Jinyue; Tan, Yahong; Yuan, Shuofeng; Shi, Guoli; Peng, Qi; Li, Yongqi; Poon, Vincent Kwok-Man; Chan, Chris Chung-Sing; Xiao, Na; Zhang, Anna Jinxia; Xie, Yubin; Li, Junhua; Luo, Hao; Fu, Yaning; Chen, Yong; Compton, Alex A; Zhang, Youming; Yang, Yang; Gao, George Fu; Hou, Hongwei; Chan, Jasper Fuk-Woo; Yin, Yizhen; Shi, Yi

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants.

Nature communications, 17(1), 1753

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Min; Yang, Jinyue; Tan, Yahong; Yuan, Shuofeng; Shi, Guoli; Peng, Qi; Li, Yongqi; Poon, Vincent Kwok-Man; Chan, Chris Chung-Sing; Xiao, Na; Zhang, Anna Jinxia; Xie, Yubin; Li, Junhua; Luo, Hao; Fu, Yaning; Chen, Yong; Compton, Alex A; Zhang, Youming; Yang, Yang; Gao, George Fu; Hou, Hongwei; Chan, Jasper Fuk-Woo; Yin, Yizhen; Shi, Yi. (2026). Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants.. Nature communications, 17(1), 1753. https://doi.org/10.1038/s41467-026-68462-9